Accenture has agreed to acquire Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry headquartered in Cork, Ireland, and serving clients around the globe. Upon close, ESP will join Accenture Industry X.0, which helps clients master the digital reinvention of industry, strengthening Accenture’s capabilities to transform manufacturing for pharmaceutical, biotech and medical device clients globally.⨠â¨ESP has long-standing industry experience in planning and implementing manufacturing solutions, with niche expertise in manufacturing execution systems (MES) and serialization. MES digitally track and document the production process, providing the groundwork for more automated and analytics-driven manufacturing and supply chains. Serialization allows life science companies to digitally track each saleable unit from the packaging line all the way to the patient. ESP will be the latest of several acquisitions Accenture has made recently to expand Accenture Industry X.0 in Europe and North America, including embedded software company Pillar Technology (US), hardware engineering firm Mindtribe (US), and strategic design consultancy designaffairs.⨠Alastair Blair, country managing director for Accenture in Ireland, said: “The planned acquisition of ESP underscores our commitment to one of Ireland’s most important and growing industries – life sciences. We continue to invest in Ireland to grow our talent and increase our capabilities to help our clients apply the very latest digital technologies and drive innovation, further strengthening the position of Ireland as a leader in this industry.”⨠In February 2017, Accenture opened The Dock, Accenture’s global innovation hub, which now employees over 300 people in Dublin, and in February 2018, Accenture acquired Rothco, a full service creative agency in Dublin with more than 170 employees.
ESP brings a team of professionals with manufacturing, process, and IT knowledge.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.